Abstract

Oxygen homeostasis is maintained in plants and animals by O2-sensing enzymes initiating adaptive responses to low O2 (hypoxia). Recently, the O2-sensitive enzyme ADO was shown to initiate degradation of target proteins RGS4/5 and IL32 via the Cysteine/Arginine N-degron pathway. ADO functions by catalysing oxidation of N-terminal cysteine residues, but despite multiple proteins in the human proteome having an N-terminal cysteine, other endogenous ADO substrates have not yet been identified. This could be because alternative modifications of N-terminal cysteine residues, including acetylation, prevent ADO-catalysed oxidation. Here we investigate the relationship between ADO-catalysed oxidation and NatA-catalysed acetylation of a broad range of protein sequences with N-terminal cysteines. We present evidence that human NatA catalyses N-terminal cysteine acetylation in vitro and in vivo. We then show that sequences downstream of the N-terminal cysteine dictate whether this residue is oxidised or acetylated, with ADO preferring basic and aromatic amino acids and NatA preferring acidic or polar residues. In vitro, the two modifications appear to be mutually exclusive, suggesting that distinct pools of N-terminal cysteine proteins may be acetylated or oxidised. These results reveal the sequence determinants that contribute to N-terminal cysteine protein modifications, with implications for O2-dependent protein stability and the hypoxic response.

Heathcote et al. show that enzymes catalysing N-terminal cysteine oxidation and acetylation have distinct substrate preferences. The modifications are mutually exclusive in vitro, with implications for protein stability and the hypoxic response.

Details

Title
N-terminal cysteine acetylation and oxidation patterns may define protein stability
Author
Heathcote, Karen C. 1   VIAFID ORCID Logo  ; Keeley, Thomas P. 2 ; Myllykoski, Matti 3   VIAFID ORCID Logo  ; Lundekvam, Malin 3 ; McTiernan, Nina 3   VIAFID ORCID Logo  ; Akter, Salma 4 ; Masson, Norma 2 ; Ratcliffe, Peter J. 5   VIAFID ORCID Logo  ; Arnesen, Thomas 6   VIAFID ORCID Logo  ; Flashman, Emily 7   VIAFID ORCID Logo 

 University of Oxford, Department of Chemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Ludwig Institute for Cancer Research, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830) 
 University of Oxford, Ludwig Institute for Cancer Research, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Bergen, Department of Biomedicine, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443) 
 University of Oxford, Department of Chemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Oxford, Ludwig Institute for Cancer Research, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830) 
 University of Bergen, Department of Biomedicine, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443); Haukeland University Hospital, Department of Surgery, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393) 
 University of Oxford, Department of Biology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
Pages
5360
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3072089704
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.